

MSP Process for Requesting Minimally Attended or Periodically Unattended (MAMS/PUMS) Endorsements



#1

Meet Automation and Safety Requirements

Automation, alarm, and redundancy requirements as described in [NVIC 01-13 Enclosure \(2\) Section 3.2.1 Machinery Space Attendance](#).

#2

Submit Automation Test Procedures

Submit Periodic Safety Test Procedures (PSTP's) to the Authorized Classification Society (ACS) or the Marine Safety Center (MSC). MSC will review in accordance with [MTN 02-11 CH-1](#).

If ACS is authorized under 46 CFR 8.420, they may approve the PSTP's on behalf of the USCG. In such cases, MSC must still review any "general alternative" request in accordance with section 6. of [PRG E2-25](#).

In lieu of USCG testing, the authorized ACS may certify to the OCMI that the PSTP's are satisfactory. Where ACS testing is accepted, the USCG Marine Inspector (MI) may conduct a sampling of onboard operational testing.

#3

Amendment of Certificate of Inspection (COI)

Once requirements are satisfied, the OCMI will update the COI with the applicable MAMS or PUMS endorsement.

#4

Request Interim MAMS/PUMS (if necessary)

If not fully compliant at reflag, a MAMS/PUMS endorsement may be requested if NVIC 01-13 Enclosure (2) Section 3.2.1.4 requirements are met.

Vessel must identify compliance gaps. Then the OCMI will issue a CG-835V requiring correction by the next credit dry-dock (excluding UWILD). Until any identified gaps are resolved, the manning levels specified in the manning block on the COI will reflect those of a fully manned engine room. The COI will be endorsed for MAMS or PUMS as applicable.

#5

Reduced Manning (if requested)

Following a trial period (Enclosure 2 of NVIC 01-13 Section 3.2.2.2), the OCMI will review the machinery logs and alarm records, including the watch schedule, and may conduct interviews based on outcome of the review.

Prior to granting a reduced manning level, an onboard observation (underway) by the USCG may be required. The MI will only conduct this observation if clear objective evidence is present, based on the results of the trial period and MI review.